Effectiveness of tobramycin conjugated to iron oxide nanoparticles in treating infection in cystic fibrosis
2013
Cystic fibrosis (CF) is an inherited childhood-onset life-shortening disease. It is characterized by increased respiratory
production, leading to airway obstruction, chronic lung infection and inflammatory reactions. The most common bacteria
causing persisting infections in people with CF is Pseudomonas aeruginosa . Superparamagnetic Fe3O4 iron oxide
nanoparticles (NPs) conjugated to the antibiotic (tobramycin), guided by a gradient of the magnetic field or subjected to
an oscillating magnetic field, show promise in improving the drug delivery across the mucus and P. aeruginosa biofilm
to the bacteria. The question remains whether tobramycin needs to be released from the NPs after the penetration of the
mucus barrier in order to act upon the pathogenic bacteria. We used a zero-length 1-ethyl-3-[3-dimethylaminopropyl]
carbodiimide hydrochloride (EDC) crosslinking agent to couple tobramycin, via its amine groups, to the carboxyl groups
on Fe 3 O 4 NPs capped with citric acid. The therapeutic efficiency of Fe 3 O 4 NPs attached to the drug versus that of the
free drug was investigated in P. aeruginosa culture.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
4
Citations
NaN
KQI